Advanced Healthcare Materials · 2016 · 47 citations · 31 references
PharmacyMolecular PharmaceuticsOncologyDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer Drug DeliveryCancer NanomedicineNanomaterials For Drug DeliveryNanomedicineNanoparticle Delivery SystemsNanoparticle DesignCancer NanotherapyEukaryotic Initiation Factor 4EGene Delivery NanoparticlesLipid NanoparticlesMultifunctional NanoparticlesNanoparticle-based ChemotherapyNanoparticlesTumor-targeted Drug Delivery
RNAi-mediated knockdown of oncogenes associated with drug resistance can potentially enhance the efficacy of chemotherapy. Here, we have designed and developed targeted dual pH-sensitive lipid-siRNA self-assembly nanoparticles, RGD-PEG(HZ)-ECO/siRNA, which can efficiently silence the oncogene, eukaryotic translation initiation factor 4E (eIF4E), and consequently resensitize triple-negative breast tumors to paclitaxel. The dual pH-sensitive function of these nanoparticles facilitates effective cytosolic siRNA delivery in cancer cells, both in vitro and in vivo. Intravenous injection of RGD-PEG(HZ)-ECO/siRNA nanoparticles (1.0 mg-siRNA/kg) results in effective gene silencing for at least one week in MDA-MB-231 tumors. In addition, treatment of athymic nude mice with RGD-PEG(HZ)-ECO/sieIF4E every 6 days for 6 weeks down-regulates the overexpression of eIF4E and resensitizes paclitaxel-resistant MDA-MB-231 tumors to paclitaxel, resulting in significant tumor regression at a low dose, with negligible side effects. Moreover, repeated injections of the RGD-PEG(HZ)-ECO/siRNA nanoparticles in immunocompetent mice result in minimal immunogenicity, demonstrating their safety and low toxicity. These multifunctional lipid/siRNA nanoparticles constitute a versatile platform of delivery of therapeutic siRNA for treating cancer and other human diseases.
31
Dmitri B. Kirpotin, Daryl C. Drummond, Yi Shao et al. · Cancer Research · 2006 · 1.1K citations · Full text
Differential Requirements for eIF4E Dose in Normal Development and Cancer
Morgan Truitt, Crystal S. Conn, Zhen Shi et al. · Cell · 2015 · 396 citations · Full text
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Lise Boussemart, Hélène Malka-Mahieu, Isabelle Girault et al. · Nature · 2014 · 360 citations
Medicine, Cancer Biology, Oncology +11